Previous 10 | Next 10 |
Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 million, extending cas...
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the compensation committee of Sema4’s board of directors granted newly-hired employees ...
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Directors Eric Schadt, fou...
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thursday, May 12, 2022. On the same d...
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform, Centrellis ® , has earned Certified status for information security by the Heal...
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently publish...
- The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4’s Chief Medical Science Officer Will Discuss the Study at the Community Oncology Alliance’s Annual Con...
Sema4 Holdings Corp. (SMFR) Q4 2021 Earnings Conference Call March 14, 2022 4:30 PM ET Company Participants Joel Kaufman - VP Finance & Corporate Development Eric Schadt - Founder and Chief Executive Officer Isaac Ro - Chief Financial Officer Conference Call Participants Brandon Couillard...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2021 Q4 earnings call. For further details see: Sema4 Holdings Corp. 2021 Q4 - Results - Earnings Call Presentation
Sema4 press release (NASDAQ:SMFR): Q4 GAAP EPS of -$0.17. Revenue of $57.8M (-9.6% Y/Y). Total cash and cash equivalents were $400.6 million as of December 31, 2021. For further details see: Sema4 GAAP EPS of -$0.17, revenue of $57.8M
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...